NCT00720135已完成1 期
A Phase I Study of De-Immunized DI-Leu16-IL2 Immunocytokine in Patients With B-Cell Non-Hodgkin Lymphoma
City of Hope Medical Center2 个研究点 分布在 1 个国家目标入组 9 人开始时间: 2008年1月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 9
- 试验地点
- 2
- 主要终点
- Maximum tolerated dose of DI-Leu16-IL2
研究概览
简要总结
RATIONALE: Biological therapies, such as fusion protein cytokine therapy, may stimulate the immune system in different ways and stop cancer cells from growing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving fusion protein cytokine therapy together with rituximab may kill more cancer cells.
PURPOSE: This phase I trial is studying the side effects and best dose of fusion protein cytokine therapy when given after rituximab in treating patients with B-cell non-Hodgkin lymphoma.
详细描述
PRIMARY OBJECTIVES:
I. To determine the maximum tolerated dose (MTD) of DI-Leu16-IL2 (DI-Leu16-IL2 immunocytokine) following peripheral blood B cell depletion with rituximab in patients with B-cell NHL.
II. To investigate the optimal biological dose (OBD) of DI-Leu16-IL2 following peripheral blood B cell depletion with rituximab in patients with B-cell NHL, which may differ from the MTD.
III. To describe the toxicities associated with the proposed DI-Leu16-IL2 regimen.
SECONDARY OBJECTIVES:
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with CD20-expressing B cell NHL that is relapsed or refractory to standard therapy; CLL/SLL with peripheral blood leukemia/lymphoma cells and high-grade lymphomas (i.e., lymphoblastic lymphoma/Burkitt lymphoma) are excluded
- •Patients must have received prior Rituxan
- •Measurable disease; in the absence of lymphadenopathy, splenomegaly with defects or measurable extramedullary disease is acceptable; however, bone marrow involvement alone will not be included in the study
- •Age >=18 years and <=65 physiologic years of age
- •KPS >= 70%
- •Life expectancy >= 12 weeks
- •Serum creatinine =< 1.5 mg/dl
- •Total WBC >= 3000/ul or absolute neutrophil count (ANC) >= 1000/ul
- •Lymphocyte count >= 0.2 x 10^3/ul
- •Platelet count >= 75,000/ul
- •Hematocrit >= 25% or hemoglobin >= 9 g/100 ml
- •Alanine aminotransferase (ALT) =< 2.5 x UNL
- •Aspartate aminotransferase (AST) =< 2.5 x UNL
- •Total bilirubin (TBili) < 1.5 x UNL
- •Sodium, potassium, and phosphorus within normal limits
- •Chest x ray (CXR) within 4 weeks prior to Day 1 with no evidence of pulmonary congestion, pleural effusions, pulmonary fibrosis, or significant emphysema; if results are questionable, subjects would have additional lung function testing to exclude clinically relevant restriction or obstruction; subjects must have an FEV-1 and DLCO of at least 65% and 50% of expected, respectively
- •Electrocardiogram (12-lead ECG)
- •Echocardiogram (or MUGA) with normal left ventricular function
- •Cardiac stress test (e.g., stress thallium scan, stress echocardiography) with normal results if subject is suspected to have coronary artery disease
- •Fasting blood glucose (FBG) < 160 and hemoglobin (Hgb) A1C < 7% for subjects with diabetes mellitus (DM) or borderline DM
- •Women of procreative potential must have negative pregnancy test within the 2-week screening phase prior to Cycle 1, and all subjects of procreative potential must use adequate birth control throughout the study; subjects of procreative potential are defined as any fertile male, and any female who has experienced menarche and has not undergone successful surgical sterilization (hysterectomy or bilateral oophorectomy) or is not post-menopausal, defined as age-related amenorrhea >= 12 months
- •Provide written informed consent prior to any screening procedures
- •Evidence of CNS lymphoma or lymphomatous meningitis
- •Prior treatment with IL-2
- •Type I hypersensitivity or anaphylactic reactions to murine proteins or to previous infusion of rituximab
- •Pregnant or lactating female
- •An immediate need for palliative radiotherapy or systemic corticosteroid therapy
- •Known intercurrent infections (including hepatitis C virus [HCV] and HIV or other conditions), or clinical evidence of these conditions
- •Actively infected with or chronic carriers of hepatitis B virus (HBV) as demonstrated by positive hepatitis B core antibody (HbcHb) or hepatitis B surface antigen (HbsAg); (subjects who are sero-positive only, i.e., surface antibody positive [HbsAg], are permitted)
- •Other significant active infection
- •Major surgery, chemotherapy, investigational agent, or radiation within 30 days of Day 1
- •Uncontrolled hypertension (diastolic >= 100 mmHg) or hypotension (systolic =< 90 mmHg)
- •History of repeated and clinically relevant episodes of syncope or other paroxysmal, ventricular, or other significant arrhythmias
- •On ECG: a marked baseline prolongation of QT/QTc interval (> grade 2 QTc interval > 470 milliseconds)
- •History of medically significant ascites requiring repetitive paracentesis
- •Previous diagnosis of Addison's disease
- •Previous diagnosis of autoimmune disease (exceptions: subjects with autoimmune thyroiditis or vitiligo may be enrolled)
- •Organ transplant recipient
- •History of prior therapy or a serious, uncontrolled medical disorder that in the investigator's opinion would impair participation in the study
- •Known hypersensitivity to Tween-80 or human immunoglobulin
- •Legal incapacity or limited legal capacity
- •Patients with bulky lymph nodes (>= 10cm) or marked splenomegaly (i.e., extending into pelvis or crossing the midline)
- •Positive anti-DI-Leu16-IL2 antibody assay (where positive is defined as > 10% of the radiolabeled DI-Leu16-IL2 reactive with the subject's serum)
排除标准
- 未提供
结局指标
主要结局
Maximum tolerated dose of DI-Leu16-IL2
时间窗: 6 weeks post cycle 1 of treatment
Optimal biologic dose of DI-Leu16-IL2
时间窗: 6 weeks after final cycle of treatment
Toxicities associated with the DI-Leu16-IL2 regimen
时间窗: 6 weeks after final cycle of treatment
次要结局
- Immunogenicity as a result of DI-Leu16-IL2 administration(Within 2 weeks following a 4 week treatment period)
- Pharmacokinetics of DI-Leu16-IL2 administration(6 weeks after final cycle of treatment)
- Clinical responses and survival(Within two weeks following completion of treatment)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube CancerFallopian Tube CancerOvarian Clear Cell CystadenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian Mixed Epithelial CarcinomaOvarian Mucinous CystadenocarcinomaOvarian Serous CystadenocarcinomaOvarian Undifferentiated AdenocarcinomaPeritoneal Cavity CancerRecurrent Ovarian Epithelial CancerStage III Ovarian Epithelial CancerStage IV Ovarian Epithelial CancerNCT00357448University of Washington11
终止
1 期
A Study of De-immunized DI-Leu16-IL2 Administered Subcutaneously in Participants With B-cell NHLB-cell Non-Hodgkin LymphomaNCT01874288Alopexx Oncology, LLC24
已完成
2 期
Hu14.18-Interleukin-2 Fusion Protein in Treating Patients With Advanced MelanomaMelanoma (Skin)NCT00109863University of Wisconsin, Madison14
已完成
2 期
Interferon-gamma or Aldesleukin and Vaccine Therapy in Treating Patients With Multiple MyelomaMultiple Myeloma and Plasma Cell NeoplasmNCT00616720Mayo Clinic15
已完成
1 期
Immunotherapy After Chemotherapy for Patients With Hormone Refractory Metastatic Prostate CancerProstate CancerNCT00283829University of Washington30